Company Announcement no. 1/2011



To: NASDAQ OMX Copenhagen A/S
Hørsholm, Denmark, February 11, 2011




LifeCycle Pharma to Present at the 13th Annual BIO CEO & Investor Conference


LifeCycle Pharma A/S (OMX: LCP) today announced that William J. Polvino, M.D.,
president and chief executive officer, will present at the 13th Annual BIO CEO
& Investor Conference at 10:30 a.m. EST, February 14, 2011, at the
Waldorf-Astoria Hotel in New York City. Dr. Polvino will provide an overview of
the company and its lead Phase 3 candidate to prevent organ transplant
rejection, LCP-Tacro.



For U.S. investor and media contacts:

John Weinberg, M.D., Senior VP, Commercial Development and Strategic Planning

LifeCycle Pharma A/S

(732) 321-3208

[email protected]



About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New Jersey, LCP is a specialty
pharmaceutical company. Clinical development is the core of LCP's efforts to
develop a product portfolio which includes the Company's lead product
candidate, LCP‐Tacro™, for immunosuppression, specifically organ
transplantation, and products to combat certain cardiovascular diseases. LCP
adapts new technologies on a fast commercial timetable. LCP's unique, patented
delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at
low‐scale up costs ‐ not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a lipid lowering product,
Fenoglide®, currently on the U.S. market and a diversified near and medium term
pipeline with three clinical stage product candidates and a number of projects
in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under
the trading symbol OMX: LCP.

For further information, please visit www.lcpharma.com.

110211 LifeCycle Pharma Present at Annual Bio Investor Conference.pdf